2023年2月22日 · Zytux (rituximab) is a monoclonal antibody that is used to treat certain types of cancer and autoimmune diseases, such as non-Hodgkin’s lymphoma, chronic lymphocytic …

Zytux™ (Rituximab, AryoGen Pharmed) used in the present study for multiple sclerosis (MS) patients is basically a biosimilar rituximab. In this observational study, a total of 100 patients …

2018年4月1日 · Zytux™ (Rituximab, AryoGen Pharmed) is the intended biosimilar product of MabThera ® (Rituximab, Roche) which has exhibited acceptable compatibility profile during …

Zytux is a biosimilar product with the generic name of Rituximab. It is a genetically engineered human-mouse chimeric monoclonal antibody produced by Chinese Hamster Ovary (CHO) …

2021年8月26日 · Here, we sought to investigate the efficacy and safety of rituximab therapy in the treatment of patients with refractory MG. Methods: In a 48-week, multicenter, open-labeled, …

2019年11月1日 · Results revealed that the Zytux™ could have a positive effect on MS patients. Anti-CD20 monoclonal antibodies such as ocrelizumab, rituximab, and ofatumumab target B …

2020年12月2日 · Most of treatment protocols of NHL and CLL contain rituximab in addition to chemotherapy, which has been associated with improved survival. The aim of this study was …

Zytux™ is supplied as a sterile, clear and colorless concentrate for solution for infusion. It is provided in vials of 10 milliliter and 50 milliliter containing 100 mg and 500 mg Rituximab, …

Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. (PubMed, Hematol Rep) - "Regarding …

2018年4月1日 · The aim of this study was to establish efficacy and safety of Zytux™ in comparison to MabThera ® in treatment of CLL. Materials and methods: Seventy CLL patients …